2014 Volume 5 Issue 1 Pages 62-65
There are many generic drugs of nafamostate mesilate (NM) in Japan, while only a few studies have compared the anticoagulant action of filter and/or circuit patency between the original and generic NMs. So, in this study, we retrospectively reviewed the medical records of maintenance hemodialysis (HD) patients who had been undergone open cardiovascular surgery. We examined the initial survival time of CHDF filter and circuit in patients who had administered either original NM (Fusan®, Torii Pharmaceuticals Co., Ltd, Tokyo, Japan) (n=22) or generic NM (Coahibitor®, Ajinomoto Pharmaceuticals Co., Ltd, Tokyo, Japan) (n=21). No difference was found in clinical parameters at the beginning of CHDF between the two groups. Mean filter and/or circuit lifespan was also identical between the both groups (1,390±433 vs. 1,225±434 min, p=0.219). The findings suggest that the generic drug has a comparable anticoagulant action to the original one in hemodialysis patients who had started CHDF treatment following open heart surgery. Additional studies will be needed whether the other generic NMs may afford an acceptable hemodiafilter lifespan in patients at a higher risk of filter and/or circuit coagulation.
